Formulation and Evaluation of Oral Soft Jelly Containing Salbutamol Sulphate for the Treatment of Asthma

Salbutamol sulphate oral soft jelly in asthma has been formulated and evaluated as the goal of current investigation. A person with inflamed, narrowed, swollen, excess mucus-producing airways, which makes breathing difficult. is used to treat chronic obstructive pulmonary disease (COPD.It works by relaxing muscle airways into lungs, it easier breathe . It functions loosening muscles lungs' facilitates breathing. available an inhaler, tablets, certain liquid dose forms, but due patient noncompliance issues, jellies containing salbutamol were developed. This study's aim create jelly, avoiding first pass effect, promotes compliance bioavailability while many negative effects conventional dosage forms simple swallow improves paediatric patients. Many patients find difficult tablets capsules, well use inhalation cases asthma. The best In vitro medication release was demonstrated (F2) batch at 85% 60 minutes. drug concentration discovered be between 98.23% 99.25%, within pharmacopoeial range 98% 101%. sulphate's UV spectra examined, that its greatest absorption occurs 217.50 nm. cost-effective also improved increase bioavailability.
 Keywords: Oral Jelly, Asthma, Patient Compliance, Sulphate, Paediatric Patients